Published in Int J Colorectal Dis on April 03, 2012
Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers. Gastroenterology (2015) 1.24
The prognostic value of microRNAs varies with patient race/ethnicity and stage of colorectal cancer. Clin Cancer Res (2013) 1.12
Prognostic role of microRNA-21 in colorectal cancer: a meta-analysis. PLoS One (2013) 1.00
MicroRNA-301a promotes migration and invasion by targeting TGFBR2 in human colorectal cancer. J Exp Clin Cancer Res (2014) 0.95
Prognostic value of miR-21 in various cancers: an updating meta-analysis. PLoS One (2014) 0.93
MicroRNAs: promising biomarkers for diagnosis and therapeutic targets in human colorectal cancer metastasis. BMB Rep (2015) 0.91
Micro-RNAs as clinical biomarkers and therapeutic targets in breast cancer: Quo vadis? World J Clin Oncol (2014) 0.87
An update on microRNAs as colorectal cancer biomarkers: where are we and what's next? Expert Rev Mol Diagn (2014) 0.87
MicroRNA-21 and the clinical outcomes of various carcinomas: a systematic review and meta-analysis. BMC Cancer (2014) 0.87
Increased expression of miR-21 predicts poor prognosis in patients with hepatocellular carcinoma. Int J Clin Exp Pathol (2015) 0.81
Manipulating miRNA Expression: A Novel Approach for Colon Cancer Prevention and Chemotherapy. Curr Pharmacol Rep (2015) 0.79
The S100P/RAGE signaling pathway regulates expression of microRNA-21 in colon cancer cells. FEBS Lett (2015) 0.75
The hallmarks of cancer. Cell (2000) 113.05
MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA (2008) 12.26
MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem (2007) 6.88
OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer (2007) 4.59
Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology (2008) 4.38
MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. Cancer Res (2008) 3.70
miR-21 plays a pivotal role in gastric cancer pathogenesis and progression. Lab Invest (2008) 2.87
MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol Cancer (2009) 2.45
MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology (2009) 2.23
MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc Natl Acad Sci U S A (2010) 1.99
MicroRNA-21 is a downstream effector of AKT that mediates its antiapoptotic effects via suppression of Fas ligand. J Biol Chem (2010) 1.94
Knockdown of miR-21 in human breast cancer cell lines inhibits proliferation, in vitro migration and in vivo tumor growth. Breast Cancer Res (2011) 1.64
Regulation of the cell cycle gene, BTG2, by miR-21 in human laryngeal carcinoma. Cell Res (2009) 1.58
MicroRNA signature analysis in colorectal cancer: identification of expression profiles in stage II tumors associated with aggressive disease. Int J Colorectal Dis (2011) 1.43
MicroRNA-21 is involved in osteosarcoma cell invasion and migration. Med Oncol (2010) 1.42
An update on the genetics of colorectal cancer. Hum Mol Genet (2004) 1.39
MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients. Cancer Sci (2011) 1.28
Quantitative stem-loop RT-PCR for detection of microRNAs. Methods Mol Biol (2011) 1.16
MicroRNA-21 modulates chemosensitivity of breast cancer cells to doxorubicin by targeting PTEN. Arch Med Res (2011) 1.16
miR-21 targets the tumor suppressor RhoB and regulates proliferation, invasion and apoptosis in colorectal cancer cells. FEBS Lett (2011) 0.99
Optimization and analysis of a quantitative real-time PCR-based technique to determine microRNA expression in formalin-fixed paraffin-embedded samples. BMC Biotechnol (2010) 0.97
Highly increased maspin expression corresponds with up-regulation of miR-21 in endometrial cancer: a preliminary report. Int J Gynecol Cancer (2011) 0.89
Analysis of microRNA expression profiles during the cell cycle in synchronized HeLa cells. BMB Rep (2009) 0.83
Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J Clin Oncol (2006) 2.57
Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells. Stem Cells Dev (2012) 2.47
MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol Cancer (2009) 2.45
Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med (2012) 1.62
MicroRNA involvement in glioblastoma pathogenesis. Biochem Biophys Res Commun (2009) 1.45
TGF-β - an excellent servant but a bad master. J Transl Med (2012) 1.41
Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy. J Exp Clin Cancer Res (2010) 1.36
Novel classes of non-coding RNAs and cancer. J Transl Med (2012) 1.35
Identification and functional screening of microRNAs highly deregulated in colorectal cancer. J Cell Mol Med (2012) 1.34
MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients. Cancer Sci (2011) 1.28
Identification of MicroRNAs associated with early relapse after nephrectomy in renal cell carcinoma patients. Genes Chromosomes Cancer (2012) 1.26
Genetic polymorphisms and microRNAs: new direction in molecular epidemiology of solid cancer. J Cell Mol Med (2012) 1.24
Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica (2013) 1.22
MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. Radiat Oncol (2012) 1.16
Gain of MYC underlies recurrent trisomy of the MYC chromosome in acute promyelocytic leukemia. J Exp Med (2010) 1.15
Evaluation of SNPs in miR-196-a2, miR-27a and miR-146a as risk factors of colorectal cancer. World J Gastroenterol (2012) 1.14
MiR-34b is associated with clinical outcome in triple-negative breast cancer patients. Diagn Pathol (2012) 1.11
MiR-210 expression in tumor tissue and in vitro effects of its silencing in renal cell carcinoma. Tumour Biol (2012) 1.08
Circulating miRNAs as new blood-based biomarkers for solid cancers. Future Oncol (2013) 1.08
microRNA-342, microRNA-191 and microRNA-510 are differentially expressed in T regulatory cells of type 1 diabetic patients. Cell Immunol (2010) 1.07
MicroRNAs and glioblastoma: roles in core signalling pathways and potential clinical implications. J Cell Mol Med (2011) 1.02
Bacteriocin synthesis in uropathogenic and commensal Escherichia coli: colicin E1 is a potential virulence factor. BMC Microbiol (2010) 1.02
MicroRNAs and their target gene networks in renal cell carcinoma. Biochem Biophys Res Commun (2011) 1.01
Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma. Med Oncol (2012) 1.00
c-Myb regulates matrix metalloproteinases 1/9, and cathepsin D: implications for matrix-dependent breast cancer cell invasion and metastasis. Mol Cancer (2012) 0.98
Brachytherapy and percutaneous stenting in the treatment of cholangiocarcinoma: a prospective randomised study. Eur J Radiol (2007) 0.98
Circulating miR-17-3p, miR-29a, miR-92a and miR-135b in serum: Evidence against their usage as biomarkers in colorectal cancer. Cancer Biomark (2012) 0.98
Expression of immune-modulatory molecules HLA-G and HLA-E by tumor cells in glioblastomas: an unexpected prognostic significance? Neuropathology (2011) 0.97
MicroRNAs involved in chemo- and radioresistance of high-grade gliomas. Tumour Biol (2013) 0.96
Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma. J Cell Mol Med (2014) 0.92
Surface-enhanced laser desorption/ionization time-of-flight proteomic profiling of breast carcinomas identifies clinicopathologically relevant groups of patients similar to previously defined clusters from cDNA expression. Breast Cancer Res (2008) 0.92
Comparison of the low-frequency magnetic field effects on bacteria Escherichia coli, Leclercia adecarboxylata and Staphylococcus aureus. Bioelectrochemistry (2004) 0.92
MicroRNAs targeting EGFR signalling pathway in colorectal cancer. J Cancer Res Clin Oncol (2013) 0.91
Complete sequence of low-copy-number plasmid MccC7-H22 of probiotic Escherichia coli H22 and the prevalence of mcc genes among human E. coli. Plasmid (2007) 0.91
Production of immune-modulatory nonclassical molecules HLA-G and HLA-E by tumor infiltrating ameboid microglia/macrophages in glioblastomas: a role in innate immunity? J Neuroimmunol (2010) 0.91
Growth/differentiation factor-15 inhibits differentiation into osteoclasts--a novel factor involved in control of osteoclast differentiation. Differentiation (2009) 0.91
Inhibition of topoisomerase IIα: novel function of wedelolactone. Cancer Lett (2011) 0.90
Small nucleolar RNAs functioning and potential roles in cancer. Tumour Biol (2014) 0.89
Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica (2013) 0.89
Serum miR-29a as a marker of multiple myeloma. Leuk Lymphoma (2012) 0.88
Common polymorphisms in GSTM1, GSTT1, GSTP1, GSTA1 and susceptibility to colorectal cancer in the Central European population. Eur J Med Res (2012) 0.88
Functionally suppressive CD8 T regulatory cells are increased in patients with multiple myeloma: a cause for immune impairment. PLoS One (2012) 0.88
Role of vimentin in regulation of monocyte/macrophage differentiation. Differentiation (2006) 0.88
PML-RARα co-operates with Sox4 in acute myeloid leukemia development in mice. Haematologica (2012) 0.87
Cardiac toxicity of targeted therapies used in the treatment for solid tumours: a review. Cardiovasc Toxicol (2012) 0.87
Mechanism of immunomodulatory drugs in multiple myeloma. Leuk Res (2012) 0.86
Dual treatment with FLT3 inhibitor SU11657 and doxorubicin increases survival of leukemic mice. Leuk Res (2006) 0.85
Akt expression and compartmentalization in prediction of clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. Int J Oncol (2012) 0.84
The role of microRNAs in mitochondria in cancer. Cancer Lett (2013) 0.84
HLA-G and HLA-E specific mRNAs connote opposite prognostic significance in renal cell carcinoma. Diagn Pathol (2012) 0.84
Effects of low-frequency magnetic fields on bacteria Escherichia coli. Bioelectrochemistry (2002) 0.84
BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy. Tumour Biol (2015) 0.83
Gene expression of somatostatin receptor 4 predicts clinical outcome of patients with metastatic neuroendocrine tumors treated with somatostatin analogs. Cancer Biother Radiopharm (2010) 0.83
The role of Aktand RAFTK in beta1 integrin mediated survival of precursor B-acute lymphoblastic leukemia cells. Leuk Lymphoma (2002) 0.83
Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry. BMC Gastroenterol (2014) 0.83
AGR2 predicts tamoxifen resistance in postmenopausal breast cancer patients. Dis Markers (2013) 0.83
Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel. Wien Klin Wochenschr (2010) 0.82
Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib. Clin Lymphoma Myeloma Leuk (2013) 0.82
Bacteriocinogeny in experimental pigs treated with indomethacin and Escherichia coli Nissle. World J Gastroenterol (2011) 0.82
Second malignancies in philadelphia-negative myeloproliferative neoplasms-single-center experience. Anticancer Res (2014) 0.82
Expression pattern of HLA class I antigens in renal cell carcinoma and primary cell line cultures: methodological implications for immunotherapy. Med Sci Monit (2009) 0.81